Literature DB >> 28260625

Cavernous sinus syndrome: A prospective study of 73 cases at a tertiary care centre in Northern India.

S Bhatkar1, M K Goyal1, A Takkar1, K K Mukherjee2, P Singh3, R Singh4, V Lal5.   

Abstract

OBJECTIVES: To study the clinical and etiological profile of patients with cavernous sinus syndrome (CSS) and identify factors which could determine the etiology and influence the outcome of these patients. PATIENTS AND METHODS: This prospective observational study included 73 consecutive patients satisfying the criteria of CSS (i.e. involvement of any 2 of the 3rd, 4th, 5th and 6th cranial nerves or any one of them with radiological evidence of cavernous sinus involvement). All these patients were subjected to detailed haematological, biochemical and radiological investigations and diagnosed and treated as per guidelines. The clinical and investigational data was recorded and analysed meticulously.
RESULTS: A definitive etiological diagnosis of CSS could be achieved in 86% of patients. Tumours, fungal infections and Tolosa Hunt syndrome (THS) were most common causes. On univariate analysis, diabetes, severe vision loss (visual acuity of <3/60 in at least one eye), and presence of nasal discharge showed a significantly positive association with a fungal CSS. Evidence of paranasal sinusitis, bone erosion and ICA (internal carotid artery) involvement on Gadolinium enhanced MRI (magnetic resonance imaging) of brain were significantly associated with a fungal CSS (p=0.0001), whereas involvement of orbital apex had a negative association with a neoplastic etiology (p=0.014). On multiple logistic regression, orbital apex involvement on MRI was associated with diagnosis of THS (p=0.019, OR: 18.7; 95% CI: 1.6-217.4) while MRI evidence of paranasal sinusitis (p=0.014, OR: 45; 95% CI: 2.1-94.3) and bone erosion ((p=0.019, OR: 12.5; 95% CI: 1.5-103) correlated with diagnosis of fungal CSS. 65.2% of patients (fungal CSS- 70%) had a good prognosis at six months follow up.
CONCLUSION: Most patients with CSS can be diagnosed accurately and managed properly with good outcomes.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aspergillus; Cavernous sinus; Mucormycosis; Painful ophthalmoplegia; Pituitary adenoma; Tolosa hunt syndrome

Mesh:

Year:  2017        PMID: 28260625     DOI: 10.1016/j.clineuro.2017.02.017

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

Review 1.  Tolosa-Hunt Syndrome: A Review of Diagnostic Criteria and Unresolved Issues.

Authors:  Paromita Dutta; Kamlesh Anand
Journal:  J Curr Ophthalmol       Date:  2021-07-05

2.  Abscess of the cavernous sinus in a child: a case report.

Authors:  Peng Sun; Yang Liu; Mading Zhou; Yutong Liu; Jianxin Du; Gao Zeng
Journal:  Childs Nerv Syst       Date:  2022-05-24       Impact factor: 1.532

3.  Recurrent Amaurosis Fugax Secondary to Tolosa-Hunt Syndrome: A Case Report and Review of Phenotypes and Pathology.

Authors:  Hassan Kesserwani; Marnix Heersink
Journal:  Cureus       Date:  2021-05-27

Review 4.  Mucormycosis of the Central Nervous System.

Authors:  Amanda Chikley; Ronen Ben-Ami; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2019-07-08

5.  Mucormycosis: An opportunistic pathogen during COVID-19.

Authors:  Iyer Mahalaxmi; Kaavya Jayaramayya; Dhivya Venkatesan; Mohana Devi Subramaniam; Kaviyarasi Renu; Padmavathi Vijayakumar; Arul Narayanasamy; Abilash Valsala Gopalakrishnan; Nachimuthu Senthil Kumar; Palanisamy Sivaprakash; Krothapalli R S Sambasiva Rao; Balachandar Vellingiri
Journal:  Environ Res       Date:  2021-07-06       Impact factor: 6.498

6.  Tolosa-Hunt Syndrome: Long-Term Outcome and Role of Steroid-Sparing Agents.

Authors:  Anupriya Arthur; Ajith Sivadasan; Pavitra Mannam; A T Prabakhar; Sanjith Aaron; Vivek Mathew; M Karthik; Rohith Ninan Benjamin; Shaikh Atif Iqbalahmed; Gideon Lyngsyun Rynjah; Mathew Alexander
Journal:  Ann Indian Acad Neurol       Date:  2020-02-25       Impact factor: 1.383

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.